NCT00568490 is a clinical trial of Tumor biopsy in Head and Neck Cancer, sponsored by Stanford University.

Who is sponsoring NCT00568490?

NCT00568490 is sponsored by Stanford University.

What drugs are being tested in NCT00568490?

Interventions in NCT00568490: Tumor biopsy, Phlebotomy.

What condition does NCT00568490 study?

NCT00568490 studies Head and Neck Cancer, Lung Cancer, Lip Cancer, Lip Neoplasms, Head and Neck Cancers.

Is NCT00568490 still recruiting?

NCT00568490 is currently recruiting now. Last updated 2 July 2025.

Last reviewed 2025-07-02 · How we verify

NCT00568490

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers

Recruiting now Last updated 2 July 2025

What this trial tests

trial testing Tumor biopsy in Head and Neck Cancer in 200 participants. Currently enrolling.

Timeline

1 September 1998

Primary endpoint
30 April 2026

30 April 2026

Quick facts

Lead sponsor	Stanford University
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	200
Start date	1 September 1998
Primary completion	30 April 2026
Estimated completion	30 April 2026
Sites	1 location across United States

Drugs / interventions tested

Tumor biopsy
Phlebotomy

Conditions studied

Head and Neck Cancer — all drugs for Head and Neck Cancer →
Lung Cancer — all drugs for Lung Cancer →
Lip Cancer — all drugs for Lip Cancer →
Lip Neoplasms — all drugs for Lip Neoplasms →

Sponsor

Stanford University

Who can join

18 and older, any sex, with Head and Neck Cancer or Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to identify and confirm new blood and tissue markers for prognosis and tumor hypoxia. Tumor hypoxia, or the condition of low oxygen in the tumor, has been shown to increase the risk of tumor spread and enhance tumor resistance to the standard treatment of radiation and chemotherapy in head and neck and lung cancers. We have recently identified several proteins or markers in the blood and in tumors (including osteopontin, lysyl oxidase, macrophage inhibiting factor and proteomic technology) in the laboratory that may be able to identify tumors with low oxygen levels or more aggressive behaving tumors.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Matricellular proteins in drug delivery: Therapeutic targets, active agents, and therapeutic localization.
Sawyer AJ, Kyriakides TR. · · 2016 · cited 38× · PMID 26763408 · DOI 10.1016/j.addr.2015.12.016
Perspectives on Hypoxia Signaling in Tumor Stroma.
Zhang Y, Coleman M, Brekken RA. · · 2021 · cited 28× · PMID 34202979 · DOI 10.3390/cancers13123070
Prognostic and Predictive Biomarkers in Head and Neck Squamous Cell Carcinoma Treated with Radiotherapy-A Systematic Review.
Schanne DH, Koch A, Elicin O, Giger R, et al · · 2022 · cited 6× · PMID 36552043 · DOI 10.3390/biomedicines10123288

Verify or expand the search:

Other trials of Tumor biopsy

Trials testing the same drug.

NCT07233928 — Breast Cancer Organelle Properties and Protein Expression Atlas in the Three Immunohistochemical Subtypes of Breast Canc · NA · recruiting
NCT06865677 — Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas · Phase 2 · terminated
NCT05009979 — 18F-DCFPyL PET/CT in Hepatocellular Carcinoma · Phase 2 · terminated
NCT06146738 — The PALSUR-study: Palliative Care Versus Surgery in High-grade Glioma Patients (ENCRAM 2203) · recruiting
NCT06146725 — The RESBIOP-study: Resection Versus Biopsy in High-grade Glioma Patients (ENCRAM 2202) · recruiting

Other recruiting trials for Head and Neck Cancer

Currently open trials in the same condition.

NCT07318220 — Prehabilitation Protocol for Head and Neck Cancer Patients · NA · recruiting
NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
NCT07467083 — Development and Application of a Nurse-Led Preemptive Symptom Management Protocol for Head and Neck Cancer Patients Unde · Phase 3 · recruiting
NCT07209189 — Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-esca · Phase 2 · recruiting
NCT06837480 — Photobiomodulation in Head and Neck Cancer-Related Chronic Lymphedema · NA · recruiting

Other Stanford University trials

Trials by the same sponsor.

NCT05945147 — Ketamine and Midazolam Infusions for CRPS: Feasibility Study · Phase 2 · withdrawn
NCT04225949 — Patients Understanding of PROM Graphs · NA · withdrawn
NCT06273098 — School-Based Bladder Health Intervention · NA · withdrawn
NCT04652635 — Management of Nailbed Injuries · NA · withdrawn
NCT05443503 — Stanford Spine Keeper - Managing Your Low Back Pain · NA · suspended

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00568490 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Stanford University
Last refreshed: 2 July 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00568490.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing